메뉴 건너뛰기




Volumn 10, Issue 4, 2017, Pages

Reassessing Phase II Heart Failure Clinical Trials: Consensus Recommendations

(40)  Butler, Javed a   Hamo, Carine E a   Udelson, James E b   O'Connor, Christopher c   Sabbah, Hani N d   Metra, Marco e,q   Shah, Sanjiv J f   Kitzman, Dalane W g   Teerlink, John R h   Bernstein, Harold S i   Brooks, Gabriel j   Depre, Christophe k   Desouza, Mary M l   Dinh, Wilfried m,n   Donovan, Mark l   Frische Danielson, Regina o,p   Frost, Robert J l   Garza, Dahlia q   Gohring, Udo Michael q   Hellawell, Jennifer p   more..


Author keywords

clinical trial; heart failure; mortality; safety; United States Food and Drug Administration

Indexed keywords

BIOLOGICAL MARKER; DOBUTAMINE; LEVOSIMENDAN; TOLVAPTAN; CARDIOVASCULAR AGENT;

EID: 85017581011     PISSN: 19413289     EISSN: 19413297     Source Type: Journal    
DOI: 10.1161/CIRCHEARTFAILURE.116.003800     Document Type: Review
Times cited : (13)

References (39)
  • 3
    • 79952444246 scopus 로고    scopus 로고
    • Forecasting the future of cardiovascular disease in the United States: A policy statement from the American Heart Association
    • American Heart Association Advocacy Coordinating Committee; Stroke Council; Council on Cardiovascular Radiology and Intervention; Council on Clinical Cardiology; Council on Epidemiology and Prevention; Council on Arteriosclerosis; Thrombosis and Vascular Biology; Council on Cardiopulmonary; Critical Care; Perioperative and Resuscitation; Council on Cardiovascular Nursing; Council on the Kidney in Cardiovascular Disease; Council on Cardiovascular Surgery and Anesthesia, and Interdisciplinary Council on Quality of Care and Outcomes Research b013e31820a55f5
    • Heidenreich PA, Trogdon JG, Khavjou OA, Butler J, Dracup K, Ezekowitz MD, Finkelstein EA, Hong Y, Johnston SC, Khera A, Lloyd-Jones DM, Nelson SA, Nichol G, Orenstein D, Wilson PW, Woo YJ, American Heart Association Advocacy Coordinating Committee; Stroke Council; Council on Cardiovascular Radiology and Intervention; Council on Clinical Cardiology; Council on Epidemiology and Prevention; Council on Arteriosclerosis; Thrombosis and Vascular Biology; Council on Cardiopulmonary; Critical Care; Perioperative and Resuscitation; Council on Cardiovascular Nursing; Council on the Kidney in Cardiovascular Disease; Council on Cardiovascular Surgery and Anesthesia, and Interdisciplinary Council on Quality of Care and Outcomes Research Forecasting the future of cardiovascular disease in the United States: A policy statement from the American Heart Association. Circulation 2011 123 933 944. doi: 10.1161/CIR.0b013e31820a55f5.
    • (2011) Circulation , vol.123 , pp. 933-944
    • Heidenreich, P.A.1    Trogdon, J.G.2    Khavjou, O.A.3    Butler, J.4    Dracup, K.5    Ezekowitz, M.D.6    Finkelstein, E.A.7    Hong, Y.8    Johnston, S.C.9    Khera, A.10    Lloyd-Jones, D.M.11    Nelson, S.A.12    Nichol, G.13    Orenstein, D.14    Wilson, P.W.15    Woo, Y.J.16
  • 5
  • 7
    • 33947713810 scopus 로고    scopus 로고
    • Effects of oral tolvaptan in patients hospitalized for worsening heart failure: The EVEREST Outcome Trial
    • Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators
    • Konstam MA, Gheorghiade M, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, Udelson JE, Zannad F, Cook T, Ouyang J, Zimmer C, Orlandi C, Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators Effects of oral tolvaptan in patients hospitalized for worsening heart failure: The EVEREST Outcome Trial. JAMA 2007 297 1319 1331. doi: 10.1001/jama.297.12.1319.
    • (2007) JAMA , vol.297 , pp. 1319-1331
    • Konstam, M.A.1    Gheorghiade, M.2    Burnett, J.C.3    Grinfeld, L.4    Maggioni, A.P.5    Swedberg, K.6    Udelson, J.E.7    Zannad, F.8    Cook, T.9    Ouyang, J.10    Zimmer, C.11    Orlandi, C.12
  • 10
    • 84873098252 scopus 로고    scopus 로고
    • The disconnect between phase II and phase III trials of drugs for heart failure
    • Vaduganathan M, Greene SJ, Ambrosy AP, Gheorghiade M, Butler J, The disconnect between phase II and phase III trials of drugs for heart failure. Nat Rev Cardiol 2013 10 85 97. doi: 10.1038/nrcardio.2012.181.
    • (2013) Nat Rev Cardiol , vol.10 , pp. 85-97
    • Vaduganathan, M.1    Greene, S.J.2    Ambrosy, A.P.3    Gheorghiade, M.4    Butler, J.5
  • 12
    • 84992061040 scopus 로고    scopus 로고
    • Transforming drug development in heart failure: Navigating the regulatory crossroads
    • Vaduganathan M, Butler J, Gheorghiade M, Transforming drug development in heart failure: navigating the regulatory crossroads. Circ Heart Fail 2016 9 e003192. doi: 10.1161/CIRCHEARTFAILURE.116.003192.
    • (2016) Circ Heart Fail , vol.9 , pp. e003192
    • Vaduganathan, M.1    Butler, J.2    Gheorghiade, M.3
  • 14
    • 66949126764 scopus 로고    scopus 로고
    • Are BNP changes during hospitalization for heart failure a reliable surrogate for predicting the effects of therapies on post-discharge mortality?
    • Gheorghiade M, Pang PS, Are BNP changes during hospitalization for heart failure a reliable surrogate for predicting the effects of therapies on post-discharge mortality? J Am Coll Cardiol 2009 53 2349 2352. doi: 10.1016/j.jacc.2009.01.075.
    • (2009) J Am Coll Cardiol , vol.53 , pp. 2349-2352
    • Gheorghiade, M.1    Pang, P.S.2
  • 15
    • 68849114272 scopus 로고    scopus 로고
    • Biomarker-guided therapy in chronic heart failure: A meta-Analysis of randomized controlled trials
    • Felker GM, Hasselblad V, Hernandez AF, O'Connor CM, Biomarker-guided therapy in chronic heart failure: A meta-Analysis of randomized controlled trials. Am Heart J 2009 158 422 430. doi: 10.1016/j.ahj.2009.06.018.
    • (2009) Am Heart J , vol.158 , pp. 422-430
    • Felker, G.M.1    Hasselblad, V.2    Hernandez, A.F.3    O'Connor, C.M.4
  • 16
    • 0037142946 scopus 로고    scopus 로고
    • Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): A randomised double-blind trial
    • Steering Committee and Investigators of the Levosimendan Infusion versus Dobutamine (LIDO) Study
    • Follath F, Cleland JG, Just H, Papp JG, Scholz H, Peuhkurinen K, Harjola VP, Mitrovic V, Abdalla M, Sandell EP, Lehtonen L, Steering Committee and Investigators of the Levosimendan Infusion versus Dobutamine (LIDO) Study Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): A randomised double-blind trial. Lancet 2002 360 196 202
    • (2002) Lancet , vol.360 , pp. 196-202
    • Follath, F.1    Cleland, J.G.2    Just, H.3    Papp, J.G.4    Scholz, H.5    Peuhkurinen, K.6    Harjola, V.P.7    Mitrovic, V.8    Abdalla, M.9    Sandell, E.P.10    Lehtonen, L.11
  • 18
    • 77955293973 scopus 로고    scopus 로고
    • Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: A meta-Analytic approach
    • Kramer DG, Trikalinos TA, Kent DM, Antonopoulos GV, Konstam MA, Udelson JE, Quantitative evaluation of drug or device effects on ventricular remodeling as predictors of therapeutic effects on mortality in patients with heart failure and reduced ejection fraction: A meta-Analytic approach. J Am Coll Cardiol 2010 56 392 406. doi: 10.1016/j.jacc.2010.05.011.
    • (2010) J Am Coll Cardiol , vol.56 , pp. 392-406
    • Kramer, D.G.1    Trikalinos, T.A.2    Kent, D.M.3    Antonopoulos, G.V.4    Konstam, M.A.5    Udelson, J.E.6
  • 19
    • 0038690110 scopus 로고    scopus 로고
    • Effects of ACE-inhibitors and beta-blockers on left ventricular remodeling in chronic heart failure
    • Khattar RS, Effects of ACE-inhibitors and beta-blockers on left ventricular remodeling in chronic heart failure. Minerva Cardioangiol 2003 51 143 154
    • (2003) Minerva Cardioangiol , vol.51 , pp. 143-154
    • Khattar, R.S.1
  • 20
    • 77954739690 scopus 로고    scopus 로고
    • Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-To-moderate heart failure and left ventricular systolic dysfunction
    • Udelson JE, Feldman AM, Greenberg B, Pitt B, Mukherjee R, Solomon HA, Konstam MA, Randomized, double-blind, multicenter, placebo-controlled study evaluating the effect of aldosterone antagonism with eplerenone on ventricular remodeling in patients with mild-To-moderate heart failure and left ventricular systolic dysfunction. Circ Heart Fail 2010 3 347 353. doi: 10.1161/CIRCHEARTFAILURE.109.906909.
    • (2010) Circ Heart Fail , vol.3 , pp. 347-353
    • Udelson, J.E.1    Feldman, A.M.2    Greenberg, B.3    Pitt, B.4    Mukherjee, R.5    Solomon, H.A.6    Konstam, M.A.7
  • 22
    • 84925744564 scopus 로고    scopus 로고
    • Left atrium in heart failure with preserved ejection fraction: Structure, function, and significance
    • Rossi A, Gheorghiade M, Triposkiadis F, Solomon SD, Pieske B, Butler J, Left atrium in heart failure with preserved ejection fraction: structure, function, and significance. Circ Heart Fail 2014 7 1042 1049. doi: 10.1161/CIRCHEARTFAILURE.114.001276.
    • (2014) Circ Heart Fail , vol.7 , pp. 1042-1049
    • Rossi, A.1    Gheorghiade, M.2    Triposkiadis, F.3    Solomon, S.D.4    Pieske, B.5    Butler, J.6
  • 23
    • 84867745957 scopus 로고    scopus 로고
    • The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: A phase 2 double-blind randomised controlled trial
    • for the Prospective comparison of ARNI with ARB on Management Of heart failUre with preserved ejectioN fracTion (PARAMOUNT) Investigators
    • Solomon SD, Zile M, Pieske B, Voors A, Shah A, Kraigher-Krainer E, Shi V, Bransford T, Takeuchi M, Gong J, Lefkowitz M, Packer M, McMurray JJ, for the Prospective comparison of ARNI with ARB on Management Of heart failUre with preserved ejectioN fracTion (PARAMOUNT) Investigators The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: A phase 2 double-blind randomised controlled trial. Lancet 2012 380 1387 1395. doi: 10.1016/S0140-6736(12)61227-6.
    • (2012) Lancet , vol.380 , pp. 1387-1395
    • Solomon, S.D.1    Zile, M.2    Pieske, B.3    Voors, A.4    Shah, A.5    Kraigher-Krainer, E.6    Shi, V.7    Bransford, T.8    Takeuchi, M.9    Gong, J.10    Lefkowitz, M.11    Packer, M.12    McMurray, J.J.13
  • 24
    • 84947757783 scopus 로고    scopus 로고
    • Prognostic importance of changes in cardiac structure and function in heart failure with preserved ejection fraction and the impact of spironolactone
    • Shah AM, Claggett B, Sweitzer NK, Shah SJ, Deswal A, Anand IS, Fleg JL, Pitt B, Pfeffer MA, Solomon SD, Prognostic importance of changes in cardiac structure and function in heart failure with preserved ejection fraction and the impact of spironolactone. Circ Heart Fail 2015 8 1052 1058. doi: 10.1161/CIRCHEARTFAILURE.115.002249.
    • (2015) Circ Heart Fail , vol.8 , pp. 1052-1058
    • Shah, A.M.1    Claggett, B.2    Sweitzer, N.K.3    Shah, S.J.4    Deswal, A.5    Anand, I.S.6    Fleg, J.L.7    Pitt, B.8    Pfeffer, M.A.9    Solomon, S.D.10
  • 26
    • 84877973822 scopus 로고    scopus 로고
    • Evaluative framework for phase II studies in patients with heart failure and preserved ejection fraction
    • Gheorghiade M, Vaduganathan M, Shah SJ, Evaluative framework for phase II studies in patients with heart failure and preserved ejection fraction. JACC Heart Fail 2013 1 123 126. doi: 10.1016/j.jchf.2013.01.001.
    • (2013) JACC Heart Fail , vol.1 , pp. 123-126
    • Gheorghiade, M.1    Vaduganathan, M.2    Shah, S.J.3
  • 29
    • 52949105070 scopus 로고    scopus 로고
    • The PROTECT pilot study: A randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment
    • Protect Steering Committee, Investigators, and Coordinators
    • Cotter G, Dittrich HC, Weatherley BD, Bloomfield DM, O'Connor CM, Metra M, Massie BM, Protect Steering Committee, Investigators, and Coordinators The PROTECT pilot study: A randomized, placebo-controlled, dose-finding study of the adenosine A1 receptor antagonist rolofylline in patients with acute heart failure and renal impairment. J Card Fail 2008 14 631 640. doi: 10.1016/j.cardfail.2008.08.010.
    • (2008) J Card Fail , vol.14 , pp. 631-640
    • Cotter, G.1    Dittrich, H.C.2    Weatherley, B.D.3    Bloomfield, D.M.4    O'Connor, C.M.5    Metra, M.6    Massie, B.M.7
  • 30
    • 80054753558 scopus 로고    scopus 로고
    • Worsening kidney function in decompensated heart failure: Treat the heart, don't mind the kidney
    • Ruggenenti P, Remuzzi G, Worsening kidney function in decompensated heart failure: Treat the heart, don't mind the kidney. Eur Heart J 2011 32 2476 2478. doi: 10.1093/eurheartj/ehr242.
    • (2011) Eur Heart J , vol.32 , pp. 2476-2478
    • Ruggenenti, P.1    Remuzzi, G.2
  • 33
    • 0021666221 scopus 로고
    • Procedures for comparing samples with multiple endpoints
    • O'Brien PC, Procedures for comparing samples with multiple endpoints. Biometrics 1984 40 1079 1087
    • (1984) Biometrics , vol.40 , pp. 1079-1087
    • O'Brien, P.C.1
  • 34
    • 84873666783 scopus 로고    scopus 로고
    • Evaluating treatment efficacy by multiple end points in phase II acute heart failure clinical trials: Analyzing data using a global method
    • Sun H, Davison BA, Cotter G, Pencina MJ, Koch GG, Evaluating treatment efficacy by multiple end points in phase II acute heart failure clinical trials: Analyzing data using a global method. Circ Heart Fail 2012 5 742 749. doi: 10.1161/CIRCHEARTFAILURE.112.969154.
    • (2012) Circ Heart Fail , vol.5 , pp. 742-749
    • Sun, H.1    Davison, B.A.2    Cotter, G.3    Pencina, M.J.4    Koch, G.G.5
  • 36
    • 1042278919 scopus 로고    scopus 로고
    • Selection of endpoints for heart failure clinical trials
    • Zanolla L, Zardini P, Selection of endpoints for heart failure clinical trials. Eur J Heart Fail 2003 5 717 723
    • (2003) Eur J Heart Fail , vol.5 , pp. 717-723
    • Zanolla, L.1    Zardini, P.2
  • 37
    • 0033564460 scopus 로고    scopus 로고
    • Combining mortality and longitudinal measures in clinical trials
    • Finkelstein DM, Schoenfeld DA, Combining mortality and longitudinal measures in clinical trials. Stat Med 1999 18 1341 1354
    • (1999) Stat Med , vol.18 , pp. 1341-1354
    • Finkelstein, D.M.1    Schoenfeld, D.A.2
  • 38
    • 84994184221 scopus 로고    scopus 로고
    • Composite end points in acute heart failure research: Data simulations illustrate the limitations
    • Brown PM, Anstrom KJ, Felker GM, Ezekowitz JA, Composite end points in acute heart failure research: data simulations illustrate the limitations. Can J Cardiol 2016 32 1356.e21 1356.e28. doi: 10.1016/j.cjca.2016.02.067.
    • (2016) Can J Cardiol , vol.32 , pp. 1356e21-1356e28
    • Brown, P.M.1    Anstrom, K.J.2    Felker, G.M.3    Ezekowitz, J.A.4


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.